World – Iran
Dr Obaidi Amir Radwanian, executive director of the company, said Gloriba was unveiled in August 2016 in the presence of the Health Minister, Qazi Zadeh Hashmi, and is now available in pharmacies throughout the country. The company produced the drug shortly after the launch of ampagliphosin in Europe and the US, and it is hoped that this drug will develop the confidence of doctors and patients regarding the quality of pharmaceutical products. Obaidi, especially when treating diabetes.
Adel Jahid, an expert in endocrinology and metabolism, says diabetes is not only a disorder of insulin secretion, but also the possibility of disorders in other organs in the body, such as people with glucose impairment through the kidneys and & # 39 The urinary path, which leads to In order to increase the level of glucose in the blood, Empatoglyphosin helps to control glucose by pulling it and pushing it through urine.
Ampagliphlosin belongs to the new drug class (SGLT2) (Sodium Glucose Co-Transporter 2). Its operating mechanism is quite different from the anti-diabetic drugs that are available in the Iranian market. Emapaglyphosine is the first anti-diabetic drug and only reduces death rates from the complications of heart disease in diabetics. People with diabetes are 2 to 4 times more likely than others to have a variety of cardiovascular diseases. Although there are many anti-diabetes drugs on the world market, cardiovascular disease is still responsible for more than half of all cases Mortality rates for these people.
According to Babek Sherif Kashani, a cardiologist and president of the World Cardiac Disorders Association, the main difference between this drug and diabetes than other oral treatments is his ability to reduce the death rate in patients with diabetes and cardiovascular problems by 38 per cent , Admission rates for heart failure in diabetes were 35%.